Pharming (PHAR) Wins FDA Priority Review for Joenja Pediatric Dose Expansion

Pharming (Nasdaq: PHAR) just secured a faster FDA review path for a pediatric expansion of Joenja, its rare-disease drug for APDS. The FDA has accepted the company’s supplemental New Drug Application and granted it Priority Review, setting a PDUFA target action date of January 30, 2027.

**What happened**
The sNDA seeks approval for lower doses of Joenja (leniolisib), an oral PI3K-delta inhibitor, in children aged 4 and older who weigh between 13 kg and 27 kg and have activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency affecting roughly 1 to 2 people per million. The application rests on data from an open-label, multinational, single-arm Phase III study in children aged 4 to 11, which showed improvements over 12 weeks in two hallmarks of the disease — reduced lymphadenopathy and increased naive B cells. This follows the FDA’s September 2026 expansion of Joenja to children aged 4-11 weighing at least 27 kg; the drug was originally approved in March 2023 for patients 12 and older. Priority Review is reserved for medicines the FDA judges could offer significant improvements in treating a serious condition. Pharming announced the development on September 25, 2026.

**Why it matters**
Joenja is the first and only targeted treatment for APDS, and rare-disease franchises live or die by label breadth. Each pediatric weight band the FDA approves widens the addressable patient population and deepens the drug’s moat against future competitors. Priority Review signals the agency sees genuine merit in the application, which improves the odds of a January approval and could pull revenue recognition forward in Pharming’s forecasts. For a small-cap biotech like Pharming, expanding the pediatric label is one of the cleanest growth levers available.

**What to watch**
The January 30, 2027 PDUFA date is the hard catalyst — an approval decision would open Joenja to the full pediatric population down to 13 kg. Investors should also watch for Pharming’s commercial execution updates and regulatory progress in the several other countries where leniolisib is under review, as well as readouts from its two Phase II trials in other primary immunodeficiencies.

Related reading: FDA Approves AbbVie’s Once-Daily Parkinson’s Pill Juvmo (Tavapadon) — another recent FDA decision worth knowing.

What do you think — does expanding Joenja’s label to younger kids make Pharming a more attractive rare-disease play, or is the addressable market simply too small to move the needle?

Sources:
– Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja (GlobeNewswire via TradingView, Sept 25, 2026)

Auto-posted by the Bull Lounge news desk.
Not financial advice.